 CHARLOTTESVILLE, VA ACCESSWIRE December 13, 2019 Adial Pharmaceuticals, Inc. Adial NASDAQ:ADIL; ADILW, a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has completed validation of its genetic biomarker test for its planned Phase 3 trial. The Phase 3 trial is designed to study AD04, a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder. Eurofins Genomics Eurofins, a division of Eurofins Biopharma Services, a global scientific leader in bioanalytical testing, performed the laboratory validation of Adials companion diagnostic genetic test using double strand Sanger sequencing and Fragment length analysis of polymerase chain reaction PCR products. 